Circuits regulating pleasure and happiness—mechanisms of depression

Frontiers in Human Neuroscience

Volumn 10, Issue NOV2016, 2016, Pages

  Loonen, Anton J M ^a,b   Ivanova, Svetlana A ^c,d  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b GGZ Westelijk Noord Brabant   (Netherlands)

^c MENTAL HEALTH RESEARCH INSTITUTE   (Russian Federation)

^d NATIONAL RESEARCH TOMSK POLYTECHNIC UNIVERSITY   (Russian Federation)

Author keywords

Amygdala; Basal ganglia; Depression; Habenula; Mechanism; Neuroplasticity; Stress

Indexed keywords

ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR; CYTOKINE; HYDROCORTISONE; MONOAMINE; NEUROTRANSMITTER;

ADRENERGIC SYSTEM; ARTICLE; AVOIDANCE BEHAVIOR; BASAL GANGLION; BEHAVIOR ASSESSMENT; BIOLOGICAL RHYTHM; CAUDATE NUCLEUS; CENTRAL NUCLEUS (AMYGDALA); CHILDHOOD; DEPRESSION; DISEASE PREDISPOSITION; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; EXPOSURE; GLUTAMATERGIC SYNAPSE; HAPPINESS; HUMAN; KINDLING; LIMBIC CORTEX; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MOOD DISORDER; MOTIVATION; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROIMMUNOLOGY; NEUROSECRETORY CELL; NONHUMAN; NUCLEUS ACCUMBENS CORE; NUCLEUS ACCUMBENS SHELL; PLEASURE; PREFRONTAL CORTEX; PSYCHOTHERAPY; REWARD; SEROTONINERGIC SYSTEM;

EID: 84995380533     PISSN: None     EISSN: 16625161     Source Type: Journal    
DOI: 10.3389/fnhum.2016.00571     Document Type: Article

References (198)

1. Aggleton, J. P. (ed.). (2000). The Amygdala, 2nd Edn. Oxford: Oxford University Press.
2. Aghajanian, G. K., and Sanders-Bush, E. (2002). “Serotonin,” in Neuropsychopharmacology: The Fifth Generation of Progress, eds K. L. Davis, D. Charney, J. T. Coyle, C. Nemeroff (Philadelphia: Lippincott Williams and Wilkens), 15-34.
3. Ago, J., Ishikawa, T., Matsumoto, N., Rahman, M. A., and Kamei, C. (2007). Epileptiformic activity induced by antidepressants in amygdala-kindled rats. Eur. J. Pharmacol. 560, 23-28. doi: 10.1016/j.ejphar.2006.11.050
4. Aizawa, H., Amo, R., and Okamoto, H. (2011). Phylogeny and ontogeny of the habenular structure. Front. Neurosci. 5:138. doi: 10.3389/fnins.2011.00138
5. Aizawa, H., Cui, W., Tanaka, K., and Okamoto, H. (2013). Hyperactivation of the habenula as a link between depression and sleep disturbance. Front. Hum. Neurosci. 7:826. doi: 10.3389/fnhum.2013.00826
6. al-Damluji, S. (1993). Adrenergic control of the secretion of anterior pituitary hormones. Baillieres. Clin. Endocrinol. Metab. 7, 355-392. doi: 10.1016/S0950-351X(05)80180-6
7. Alexander, G. E., DeLong, M. R., and Strick, P. L. (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 9, 357-381. doi: 10.1146/annurev.ne.09.030186.002041
8. Anand, A., and Charney, D. S. (2000). Norepinephrine dysfunction in depression. J. Clin. Psychiatry 61(Suppl. 10), 16-24.
9. Andreasen, N. C., Pressler, M., Nopoulos, P., Miller, D., and Ho, B. C. (2010). Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry 67, 255-262. doi: 10.1016/j.biopsych.2009.08.040
10. Antolin-Fontes, B., Ables, J. L., Görlich, A., and Ibañez-Tallon, I. (2015). The habenulo-interpeduncular pathway in nicotine aversion and withdrawal. Neuropharmacology 96(Pt B), 213-222. doi: 10.1016/j.neuropharm.2014.11.019
11. APA (2000). Diagnostic and Statistical Manual of Mental Disorders. Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association.
12. APA (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington, DC: American Psychiatric Association.
13. Arango, V., Ernsberger, P., Reis, D. J., and Mann, J. J. (1990). Demonstration of high- and low-affinity beta-adrenergic receptors in slide-mounted sections of rat and human brain. Brain Res. 516, 113-121. doi: 10.1016/0006-8993(90)90904-P
14. Arnsten, A. F. (2011). Catecholamine influences on dorsolateral prefrontal cortical networks. Biol. Psychiatry 69:e89-99. doi: 10.1016/j.biopsych.2011. 01.027
15. Baker, G. B., and Dewhurst, W. G. (1985). “Biochemical theories of affective disorders,” in Pharmacotherapy of Affective Disorders. Theory and Practice, eds W. G. Dewhurst and G. B. Baker (London: CroomHelm), 1-59.
16. Bao, A. M., Meynen, G., and Swaab, D. F. (2008). The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res. Rev. 57, 531-553. doi: 10.1016/j.brainresrev.2007.04.005
17. Barton, M. E., and Shannon, H. E. (2005). The seizure-related phenotype of brain-derived neurotrophic factor knockdown mice. Neuroscience 136, 563-569. doi: 10.1016/j.neuroscience.2005.08.008
18. Bartrop, R. W., Luckhurst, E., Lazarus, L., Kiloh, L. G., and Penny, R. (1977). Depressed lymphocyte function after bereavement. Lancet 1, 834-836. doi: 10.1016/S0140-6736(77)92780-5
19. Benarroch, E. E. (2015). Habenula: recently recognized functions and potential clinical relevance. Neurology 85, 992-1000. doi: 10.1212/WNL.0000000000001937
20. Bernardino, L., Ferreira, R., Cristóvao, A. J., Sales, F., and Malva, J. O. (2005a). Inflammation and neurogenesis in temporal lobe epilepsy. Curr. Drug Targets CNS Neurol. Disord. 4, 349-360. doi: 10.2174/1568007054546171
21. Bernardino, L., Xapelli, S., Silva, A. P., Jakobsen, B., Poulsen, F. R., Oliveira, C. R., et al. (2005b). Modulator effects of interleukin-1beta and tumor necrosis factor-alpha on AMPA-induced excitotoxicity in mouse organotypic hippocampal slice cultures. J. Neurosci. 25, 6734-6744. doi: 10.1523/JNEUROSCI.1510-05.2005
22. Berumen, L. C., Rodríguez, A., Miledi, R., and García-Alcocer, G. (2012). Serotonin receptors in hippocampus. ScientificWorldJournal 2012:823493. doi: 10.1100/2012/823493
23. Binder, D. K., Croll, S. D., Gall, C. M., and Scharfman, H. E. (2001). BDNF and epilepsy: too much of a good thing? Trends Neurosci. 24, 47-53. doi: 10.1016/S0166-2236(00)01682-9
24. Bocquet-Appel, J. P., and Bacro, J. N. (1997). Brief communication: estimates of some demographic parameters in a Neolithic rock-cut chamber (approximately 2000 BC) using iterative techniques for aging and demographic estimators. Am. J. Phys. Anthropol. 102, 569-575.
25. Bombardi, C. (2014). Neuronal localization of the 5-HT2 receptor family in the amygdaloid complex. Front. Pharmacol. 5:68. doi: 10.3389/fphar.2014.00068
26. Bonhomme, N., and Esposito, E. (1998). Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: a review. J. Clin. Psychopharmacol. 18, 447-454. doi: 10.1097/00004714-199812000-00005
27. Bromberg-Martin, E. S., Matsumoto, M., Nakahara, H., and Hikosaka, O. (2010). Multiple timescales of memory in lateral habenula and dopamine neurons. Neuron 67, 499-510. doi: 10.1016/j.neuron.2010.06.031
28. Brunson, K. L., Schultz, L., and Baram, T. Z. (1998). The in vivo proconvulsant effects of corticotropin releasing hormone in the developing rat are independent of ionotropic glutamate receptor activation. Brain Res. Dev. Brain Res. 111, 119-128. doi: 10.1016/S0165-3806(98)00130-8
29. Bunney, B. G., and Bunney, W. E. (2012). Rapid-acting antidepressant strategies: mechanisms of action. Int. J. Neuropsychopharmacol. 15, 695-713. doi: 10.1017/S1461145711000927
30. Bunney, W. E., and Bunney, B. G. (2000). Molecular clock genes in man and lower animals: possible implications for circadian abnormalities in depression. Neuropsychopharmacology 22, 335-345. doi: 10.1016/S0893-133X(99)00145-1
31. Capuron, L., and Miller, A. H. (2011). Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol. Ther. 130, 226-238. doi: 10.1016/j.pharmthera.2011.01.014
32. Castrén, E. (2004a). Neurotrophins as mediators of drug effects on mood, addiction, and neuroprotection. Mol. Neurobiol. 29, 289-302. doi: 10.1385/MN:29:3:289
33. Castrén, E. (2004b). Neurotrophic effects of antidepressant drugs. Curr. Opin. Pharmacol. 4, 58-64. doi: 10.1016/j.coph.2003.10.004
34. Castrén, E., Võikar, V., and Rantamäki, T. (2007). Role of neurotrophic factors in depression. Curr. Opin. Pharmacol. 7, 18-21. doi: 10.1016/j.coph.2006.08.009
35. Cooper, J. R., Bloom, F. E., and Roth, R. H. (2003). The Biochemical Basis of Neuropsychopharmacology. Oxford: Oxford University Press.
36. Coppen, A. (1967). The biochemistry of affective disorders. Br. J. Psychiatry 113, 1237-1264. doi: 10.1192/bjp.113.504.1237
37. Cutsuridis, V., and Wennekers, T. (2009). Hippocampus, microcircuits and associative memory. Neural Netw. 22, 1120-1128. doi: 10.1016/j.neunet.2009.07.009
38. Czéh, B., and Lucassen, P. J. (2007). What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated? Eur. Arch. Psychiatry Clin. Neurosci. 257, 250-260. doi: 10.1007/s00406-007-0728-0
39. Czéh, B., Müller-Keuker, J. I., Rygula, R., Abumaria, N., Hiemke, C., Domenici, E., et al. (2007). Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment. Neuropsychopharmacology 32, 1490-1503. doi: 10.1038/sj.npp.1301275
40. Dalley, J. W., Mar, A. C., Economidou, D., and Robbins, T. W. (2008). Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry. Pharmacol. Biochem. Behav. 90, 250-260. doi: 10.1016/j.pbb.2007.12.021
41. Dantzer, J. (2007). “Expression and action of cytokines in the brain: mechanisms and pathophysiological Implications,” in Psychoneuroimmunology, 4th Edn., ed R. Ader (Amsterdam: Elsevier), 271-280.
42. De Graaf, R., Ten Have, M., Van Dorsselaer, S. (2010). De Psychische Gezondheid van de Nederlandse Bevolking. NEMESIS-2: Opzet en Eerste Resultaten. Utrecht: Trimbos Instituut.
43. De Kloet, E. R., Joëls, M., and Holsboer, F. (2005). Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. 6, 463-475. doi: 10.1038/nrn1683
44. Diaz, S. L., Doly, S., Narboux-Nême, N., Fernández, S., Mazot, P., Banas, S. M., et al. (2012). 5-HT(2B) receptors are required for serotonin-selective antidepressant actions. Mol. Psychiatry 17, 154-163. doi: 10.1038/mp.2011.159
45. Eichenbaum, H. (2006). Remembering: functional organization of the declarative memory system. Curr. Biol. 16, R643-R645. doi: 10.1016/j.cub.2006.07.026
46. Erdeljan, P., MacDonald, J. F., and Matthews, S. G. (2001). Glucocorticoids and serotonin alter glucocorticoid receptor (GR) but not mineralocorticoid receptor (MR) mRNA levels in fetal mouse hippocampal neurons, in vitro. Brain Res. 896, 130-136. doi: 10.1016/S0006-8993(01)02075-3
47. Eshed, V., Gopher, A., Gage, T. B., and Hershkovitz, I. (2004). Has the transition to agriculture reshaped the demographic structure of prehistoric populations? New evidence from the Levant. Am. J. Phys. Anthropol. 124, 315-329. doi: 10.1002/ajpa.10332
48. Esposito, S., Prange, A. J. Jr., and Golden, R. N. (1997). The thyroid axis and mood disorders: overview and future prospects. Psychopharmacol. Bull. 33, 205-217.
49. Euston, D. R., Gruber, A. J., and McNaughton, B. L. (2012). The role of medial prefrontal cortex in memory and decision making. Neuron 76, 1057-1070. doi: 10.1016/j.neuron.2012.12.002
50. Fava, G. A. (1994). Affective disorders and endocrine disease. New insights from psychosomatic studies. Psychosomatics 35, 341-353. doi: 10.1016/S0033-3182(94)71755-2
51. Feighner, J. P. (1999). Mechanismof action of antidepressant medications. J. Clin. Psychiatry 60(Suppl. 4), 4-11.
52. Fleming, J. (1989). Sleep architecture changes in depression: interesting finding or clinically useful. Prog. Neuropsychopharmacol. Biol. Psychiatry 13, 419-429. doi: 10.1016/0278-5846(89)90130-9
53. Freis, E. D. (1954). Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N. Engl. J. Med. 251, 1006-1008. doi: 10.1056/NEJM195412162512504
54. Friedman, W. (2012). “Chapter 29 - growth factors,” in Basic Neurochemistry: Principles of Molecular, Cellular, and Medical Neurobiology, 8th Edn., eds S. Brady, G. Siegel, R. W. Albers and D. Price (Amsterdam: Elsevier), 546-557.
55. Fuchs, E., Flugge, G., and Czeh, B. (2006). Remodeling of neuronal networks by stress. Front. Biosci. 11, 2746-2758. doi: 10.2741/2004
56. Fuster, J. M. (2008). The Prefrontal Cortex, 4th Edn. Amsterdam: Academic Press.
57. Gerber, P. E., and Lynd, L. D. (1998). Selective serotonin-reuptake inhibitor-induced movement disorders. Ann. Pharmacother. 32, 692-698. doi: 10.1345/aph.17302
58. Gibbison, B., Angelini, G. D., and Lightman, S. L. (2013). Dynamic output and control of the hypothalamic-pituitary-adrenal axis in critical illness and major surgery. Br. J. Anaesth. 111, 347-360. doi: 10.1093/bja/aet077
59. Graeber, M. B. (2010). Changing face of microglia. Science 330, 783-788. doi: 10.1126/science.1190929
60. Graeff, F. G., Guimarães, F. S., De Andrade, T. G., and Deakin, J. F. (1996). Role of 5-HT in stress, anxiety, and depression. Pharmacol. Biochem. Behav. 54, 129-141. doi: 10.1016/0091-3057(95)02135-3
61. Groenewegen, H. J. (2003). The basal ganglia and motor control. Neural Plast. 10, 107-120. doi: 10.1155/NP.2003.107
62. Groenewegen, H. J. (2007). The ventral striatum as an interface between the limbic and motor systems. CNS Spectr. 12, 887-892. doi: 10.1017/S10928529000 15650
63. Guilloux, J. P., Douillard-Guilloux, G., Kota, R., Wang, X., Gardier, A. M., Martinowich, K., et al. (2012). Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol. Psychiatry 17, 1130-1142. doi: 10.1038/mp.2011.113
64. Haddad, J. J. (2008). On the mechanisms and putative pathways involving neuroimmune interactions. Biochem. Biophys. Res. Commun. 370, 531-535. doi: 10.1016/j.bbrc.2008.04.012
65. Haddad, J. J., Saadé, N. E., and Safieh-Garabedian, B. (2002). Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary-adrenal revolving axis. J. Neuroimmunol. 133, 1-19. doi: 10.1016/S0165-5728(02)00357-0
66. Haffmans, P. M., Loonen, A. J. M., and Hoencamp, E. (2006). Apractical approach to chronobiology and mood disorders. Therapeutic Values 1, 1-8.
67. Hannon, J., and Hoyer, D. (2008). Molecular biology of 5-HT receptors. Behav. Brain Res. 195, 198-213. doi: 10.1016/j.bbr.2008.03.020
68. Heimer, L. (2003). A new anatomical framework for neuropsychiatric disorders and drug abuse. Am. J. Psychiatry 160, 1726-1739. doi: 10.1176/appi.ajp.160.10.1726
69. Herbert, J. (2013). Cortisol and depression: three questions for psychiatry. Psychol. Med. 43, 449-469. doi: 10.1017/S0033291712000955
70. Hertz, L., Rothman, D. L., Li, B., and Peng, L. (2015). Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift. Front. Behav. Neurosci. 9:25. doi: 10.3389/fnbeh.2015.00025
71. Hikosaka, O. (2010). The habenula: from stress evasion to value-based decision-making. Nat. Rev. Neurosci. 11, 503-513. doi: 10.1038/nrn2866
72. Hoyer, D., Hannon, J. P., and Martin, G. R. (2002). Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71, 533-554. doi: 10.1016/S0091-3057(01)00746-8
73. Inoue, T., Kitaichi, Y., and Koyama, T. (2011). SSRIs and conditioned fear. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 1810-1819. doi: 10.1016/j.pnpbp.2011.09.002
74. Ising, M., Künzel, H. E., Binder, E. B., Nickel, T., Modell, S., and Holsboer, F. (2005). The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 1085-1093. doi: 10.1016/j.pnpbp.2005.03.014
75. Joëls, M. (2006). Corticosteroid effects in the brain: U-shape it. Trends Pharmacol. Sci. 27, 244-250. doi: 10.1016/j.tips.2006.03.007
76. Joëls, M. (2011). Impact of glucocorticoids on brain function: relevance for mood disorders. Psychoneuroendocrinology 36, 406-414. doi: 10.1016/j.psyneuen.2010.03.004
77. Joëls, M., Pu, Z., Wiegert, O., Oitzl, M. S., and Krugers, H. J. (2006). Learning under stress: how does it work? Trends Cogn. Sci. 10, 152-158. doi: 10.1016/j.tics.2006.02.002
78. Joëls, M., Sarabdjitsingh, R. A., and Karst, H. (2012). Unraveling the time domains of corticosteroid hormone influences on brain activity: rapid, slow, and chronic modes. Pharmacol. Rev. 64, 901-938. doi: 10.1124/pr.112.005892
79. Joyce, J. N., Lexow, N., Kim, S. J., Artymyshyn, R., Senzon, S., Lawrence, D., et al. (1992). Distribution of beta-adrenergic receptor subtypes in human postmortem brain: alterations in limbic regions of schizophrenics. Synapse 10, 228-246. doi: 10.1002/syn.890100306
80. Karst, H., de Kloet, E. R., and Joëls, M. (1999). Episodic corticosterone treatment accelerates kindling epileptogenesis and triggers long-term changes in hippocampal CA1 cells, in the fully kindled state. Eur. J. Neurosci. 11, 889-898. doi: 10.1046/j.1460-9568.1999.00495.x
81. Kessler, R. C. (2012). The costs of depression. Psychiatr. Clin. North Am. 35, 1-14. doi: 10.1016/j.psc.2011.11.005
82. Kettenmann, H., Kirchhoff, F., and Verkhratsky, A. (2013). Microglia: new roles for the synaptic stripper. Neuron 77, 10-18. doi: 10.1016/j.neuron.2012.12.023
83. Khairova, R. A., Machado-Vieira, R., Du, J., and Manji, H. K. (2009). A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int. J. Neuropsychopharmacol. 12, 561-578. doi: 10.1017/S1461145709009924
84. Koob, G. F., and Le Moal, M. (1997). Drug abuse: hedonic homeostatic dysregulation. Science 278, 52-58. doi: 10.1126/science.278.5335.52
85. Koob, G. F., and Volkow, N. D. (2010). Neurocircuitry of addiction. Neuropsychopharmacology 35, 217-238. doi: 10.1038/npp.2009.110
86. Kumar, G., Couper, A., O’Brien, T. J., Salzberg, M. R., Jones, N. C., Rees, S. M., et al. (2007). The acceleration of amygdala kindling epileptogenesis by chronic low-dose corticosterone involves both mineralocorticoid and glucocorticoid receptors. Psychoneuroendocrinology 32, 834-842. doi: 10.1016/j.psyneuen.2007.05.011
87. Lai, M., McCormick, J. A., Chapman, K. E., Kelly, P. A., Seckl, J. R., and Yau, J. L. (2003). Differential regulation of corticosteroid receptors by monoamine neurotransmitters and antidepressant drugs in primary hippocampal culture. Neuroscience 118, 975-984. doi: 10.1016/S0306-4522(03)00038-1
88. Lampron, A., Elali, A., and Rivest, S. (2013). Innate immunity in the CNS: redefining the relationship between the CNS and its environment. Neuron 78, 214-232. doi: 10.1016/j.neuron.2013.04.005
89. Laplante, P., Diorio, J., and Meaney, M. J. (2002). Serotonin regulates hippocampal glucocorticoid receptor expression via a 5-HT7 receptor. Brain Res. Dev. Brain Res. 139, 199-203. doi: 10.1016/S0165-3806(02)00550-3
90. Leo, R. J. (1996). Movement disorders associated with the serotonin selective reuptake inhibitors. J. Clin. Psychiatry 57, 449-454. doi: 10.4088/JCP.v57n1002
91. Leonard, B. E. (2003). Fundamentals of Psychopharmacology, 3rd Edn. Chichester: John Wiley and Sons.
92. Leonard, B. E. (2005). The HPA and immune axes in stress: the involvement of the serotonergic system. Eur. Psychiatry 20, S302-S306. doi: 10.1016/S0924-9338(05)80180-4
93. Leonard, B. E. (2006). HPA and immune axes in stress: involvement of the serotonergic system. Neuroimmunomodulation 13, 268-276. doi: 10.1159/000104854
94. Leonard, B. E. (2007). Psychopathology of depression. Drugs Today 43, 705-716. doi: 10.1358/dot.2007.43.10.1122223
95. Leonard, B. E. (2014). Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 48, 261-267. doi: 10.1016/j.pnpbp.2013.10.018
96. Leonard, B. E., and Myint, A. (2006a). Changes in the immune system in depression and dementia: causal or coincidental effects? Dialogues Clin. Neurosci. 8, 163-174.
97. Leonard, B. E., and Myint, A. (2006b). Inflammation and depression: is there a causal connection with dementia? Neurotox. Res. 10, 149-160. doi: 10.1007/BF03033243
98. Leonard, B. E., and Myint, A. (2009). The psychoneuroimmunology of depression. Hum. Psychopharmacol. 24, 165-175. doi: 10.1002/hup.1011
99. Licinio, J., and Wong, M. L. (1997). Pathways and mechanisms for cytokine signaling of the central nervous system. J. Clin. Invest. 100, 2941-2947. doi: 10.1172/JCI119846
100. Loonen, A. J., and Ivanova, S. A. (2013). Newinsights into the mechanismof drug-induced dyskinesia. CNS Spectr. 18, 15-20. doi: 10.1017/S1092852912000752
101. Loonen, A. J., andIvanova, S. A. (2015). Circuits regulating pleasure andhappiness: the evolution of reward-seeking and misery-fleeing behavioral mechanisms in vertebrates. Front. Neurosci. 9:394. doi: 10.3389/fnins.2015.00394
102. Loonen, A. J., and Ivanova, S. A. (2016a). Circuits regulating pleasure and happiness in major depression. Med. Hypotheses 87, 14-21. doi: 10.1016/j.mehy.2015.12.013
103. Loonen, A. J., and Ivanova, S. A. (2016b). Role of 5-HT2C receptors in dyskinesia. Int. J. Pharm. Pharm. Sci. 8, 5-10.
104. Loonen, A. J. M. (2012). Ideeën Voor een Nieuwe Maatschappij. Haarlem: Mension.
105. Loonen, A. J. M. (2013a). “Five theories of the mechanism of depression,” in Modern Problems of the Neurobiology of Depression (Tomsk; Novosibirsk: CINP Course). doi: 10.13140/RG.2.1.4317.0967
106. Loonen, A. J. M. (2013b). Het Beweeglijke Brein. De Neurowetenschappelijke Achtergronden van de Psychische Functies. Haarlem, NL: Mension. doi: 10.13140/RG.2.1.4317.0967
107. Loonen, A. J. M., and Stahl, S. M. (2011). The mechanism of drug-induced akathisia. CNS Spectr. 16, 7-10. doi: 10.1017/S1092852912000107
108. Loonen, A. J., Schellekens, A. F., and Ivanova, S. A. (2016). “Circuits regulating pleasure and happiness: a focus on addiction, beyond the ventral striatum,” in Recent Advances in Drug Addiction Research and Clinical Applications, eds W. M. Meil and C. L. Ruby (Rijeka: InTech), 1-20.
109. Lucassen, P. J., Heine, V. M., Muller, M. B., van der Beek, E. M., Wiegant, V. M., De Kloet, E. R., et al. (2006). Stress, depressionandhippocampal apoptosis. CNS Neurol. Disord. Drug. Targets 5, 531-546. doi: 10.2174/187152706778559273
110. Mackenbach, J. P., andLooman, C. W. (2013). Life expectancy andnational income in Europe, 1900-2008: an update of Preston’s analysis. Int. J. Epidemiol. 42, 1100-1110. doi: 10.1093/ije/dyt122
111. Maître, L., Moser, P., Baumann, P. A., and Waldmeier, P. C. (1980). Amine uptake inhibitors: criteria of selectivity. Acta Psychiatr. Scand. 61, 97-119.
112. Maren, S., Phan, K. L., and Liberzon, I. (2013). The contextual brain: implications for fear conditioning, extinction and psychopathology. Nat. Rev. Neurosci. 14, 417-428. doi: 10.1038/nrn3492
113. Masi, G., and Brovedani, P. (2011). The hippocampus, neurotrophic factors and depression: possible implications for the pharmacotherapy of depression. CNS Drugs 25, 913-931. doi: 10.2165/11595900-000000000-00000
114. Matsumoto, M., and Hikosaka, O. (2009). Representation of negative motivational value in the primate lateral habenula. Nat. Neurosci. 12, 77-84. doi: 10.1038/nn.2233
115. McAllister-Williams, R. H., Ferrier, I. N., and Young, A. H. (1998). Mood and neuropsychological function in depression: the role of corticosteroids and serotonin. Psychol. Med. 28, 573-584. doi: 10.1017/S0033291798006680
116. McCarthy, M. J., and Welsh, D. K. (2012). Cellular circadian clocks in mood disorders. J. Biol. Rhythms 27, 339-352. doi: 10.1177/0748730412456367
117. McDougall, I., Brown, F. H., and Fleagle, J. G. (2005). Stratigraphic placement and age of modern humans from Kibish, Ethiopia. Nature 433, 733-736. doi: 10.1038/nature03258
118. McEwen, B. S. (2012). Brain on stress: how the social environment gets under the skin. Proc. Natl. Acad. Sci. U.S.A. 109, 17180-17185. doi: 10.1073/pnas.1121254109
119. McEwen, B. S. (2015). Biomarkers for assessing population and individual health and disease related to stress and adaptation. Metab. Clin. Exp. 64, S2-S10. doi: 10.1016/j.metabol.2014.10.029
120. Melrose, S. (2015). Seasonal affective disorder: an overview of assessment and treatment approaches. Depress Res. Treat 2015:178564. doi: 10.1155/2015/178564
121. Merola, B., Longobardi, S., Colao, A., Di Somma, C., Ferone, D., Rossi, E., et al. (1994). Hypothalamic-pituitary-adrenal axis in neuropsychiatric disorders. Ann. N.Y. Acad. Sci. 741, 263-270. doi: 10.1111/j.1749-6632.1994.tb23109.x
122. Millan, M. J. (2005). Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Thérapie 60, 441-460. doi: 10.2515/therapie:2005065
123. Millan, M. J., Gobert, A., Rivet, J. M., Adhumeau-Auclair, A., Cussac, D., Newman-Tancredi, A., et al. (2000). Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur. J. Neurosci. 12, 1079-1095. doi: 10.1046/j.1460-9568.2000.00982.x
124. Miller, A. H., Maletic, V., and Raison, C. L. (2009). Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65, 732-741. doi: 10.1016/j.biopsych.2008.11.029
125. Miller, A. H., Pariante, C. M., and Pearce, B. D. (1999). Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv. Exp. Med. Biol. 461, 107-116. doi: 10.1007/978-0-585-37970-8_7
126. Miller, A. H., and Raison, C. L. (2015). The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 16, 22-34. doi: 10.1038/nri.2015.5
127. Mineka, S., Watson, D., and Clark, L. A. (1998). Comorbidity of anxiety and unipolar mood disorders. Annu. Rev. Psychol. 49, 377-412. doi: 10.1146/annurev.psych.49.1.377
128. Monti, J. M. (2011). Serotonin control of sleep-wake behavior. Sleep Med. Rev. 15, 269-281. doi: 10.1016/j.smrv.2010.11.003
129. Morita, M., and Nakayama, K. (2011). Mirtazapine in combination with perospirone synergistically enhances dopamine release in the rat prefrontal cortex via 5-HT1A receptor activation. Psychiatry Clin. Neurosci. 65, 246-253. doi: 10.1111/j.1440-1819.2011.02191.x
130. Müller, N., and Ackenheil, M. (1998). Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 22, 1-33. doi: 10.1016/S0278-5846(97)00179-6
131. Nagai, M., Kishi, K., and Kato, S. (2007). Insular cortex and neuropsychiatric disorders: a review of recent literature. Eur. Psychiatry 22, 387-394. doi: 10.1016/j.eurpsy.2007.02.006
132. Nagano, M., Liu, M., Inagaki, H., Kawada, T., and Suzuki, H. (2012). Early intervention with fluoxetine reverses abnormalities in the serotonergic system and behavior of rats exposed prenatally to dexamethasone. Neuropharmacology 63, 292-300. doi: 10.1016/j.neuropharm.2012.03.027
133. Nagaoka, T., Hirata, K., Yokota, E., and Matsu’ura, S. (2006). Paleodemography of a medieval population in Japan: analysis of human skeletal remains from the Yuigahama-minami site. Am. J. Phys. Anthropol. 131, 1-14. doi: 10.1002/ajpa.20402
134. Nebigil, C. G., Etienne, N., Schaerlinger, B., Hickel, P., Launay, J. M., and Maroteaux, L. (2001). Developmentally regulated serotonin 5-HT2B receptors. Int. J. Dev. Neurosci. 19, 365-372. doi: 10.1016/S0736-5748(01)00022-3
135. Nibuya, M., Morinobu, S., and Duman, R. S. (1995). Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 15, 7539-7547.
136. Nieuwenhuys, R. (1985). Chemoarchitecture of the Brain. Berlin: Springer-Verlag.
137. Nieuwenhuys, R., Voogd, J., and Van Huijzen, C. (2008). The Human Central Nervous System, 4th Edn. Berlin: Springer.
138. Ogren, S. O., Eriksson, T. M., Elvander-Tottie, E., D’Addario, C., Ekström, J. C., Svenningsson, P., et al. (2008). The role of 5-HT(1A) receptors in learning and memory. Behav. Brain Res. 195, 54-77. doi: 10.1016/j.bbr.2008.02.023
139. Osehobo, P., Adams, B., Sazgar, M., Xu, Y., Racine, R. J., and Fahnestock, M. (1999). Brain-derived neurotrophic factor infusion delays amygdala and perforant path kindling without affecting paired-pulse measures of neuronal inhibition in adult rats. Neuroscience 92, 1367-1375. doi: 10.1016/S0306-4522(99)00048-2
140. Pagani, L., Semenova, E. A., Moriggi, E., Revell, V. L., Hack, L. M., Lockley, S. W., et al. (2010). The physiological period length of the human circadian clock in vivo is directly proportional to period in human fibroblasts. PLoS ONE 5:e13376. doi: 10.1371/journal.pone.0013376
141. Pail, G., Huf, W., Pjrek, E., Winkler, D., Willeit, M., Praschak-Rieder, N., et al. (2011). Bright-light therapy in the treatment of mood disorders. Neuropsychobiology 64, 152-162. doi: 10.1159/000328950
142. Pare, D., and Duvarci, S. (2012). Amygdala microcircuits mediating fear expression and extinction. Curr. Opin. Neurobiol. 22, 717-723. doi: 10.1016/j.conb.2012.02.014
143. Pazos, A., Probst, A., and Palacios, J. M. (1985). Beta-adrenoceptor subtypes in the human brain: autoradiographic localization. Brain Res. 358, 324-328. doi: 10.1016/0006-8993(85)90977-1
144. Post, R. M. (2004). Neurobiology of seizures and behavioral abnormalities. Epilepsia 45, 5-14. doi: 10.1111/j.0013-9580.2004.452001.x
145. Post, R. M. (2007). Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci. Biobehav. Rev. 31, 858-873. doi: 10.1016/j.neubiorev.2007.04.003
146. Post, R. M. (2010). Mechanisms of illness progression in the recurrent affective disorders. Neurotox. Res. 18, 256-271. doi: 10.1007/s12640-010-9182-2
147. Post, R. M., Fleming, J., and Kapczinski, F. (2012). Neurobiological correlates of illness progression in the recurrent affective disorders. J. Psychiatr. Res. 46, 561-573. doi: 10.1016/j.jpsychires.2012.02.004
148. Raadsheer, F. C., Hoogendijk, W. J., Stam, F. C., Tilders, F. J., and Swaab, D. F. (1994). Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60, 436-444. doi: 10.1159/000126778
149. Raadsheer, F. C., van Heerikhuize, J. J., Lucassen, P. J., Hoogendijk, W. J., Tilders, F. J., and Swaab, D. F. (1995). Corticotropin-releasing hormone mRNAlevels in the paraventricular nucleus of patients with Alzheimer’s disease and depression. Am. J. Psychiatry 152, 1372-1376. doi: 10.1176/ajp.152.9.1372
150. Ramos, B. P., and Arnsten, A. F. (2007). Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol. Ther. 113, 523-536. doi: 10.1016/j.pharmthera.2006.11.006
151. Reznikoff, G. A., Manaker, S., Rhodes, C. H., Winokur, A., and Rainbow, T. C. (1986). Localization and quantification of beta-adrenergic receptors in human brain. Neurology 36, 1067-1073. doi: 10.1212/WNL.36.8.1067
152. Riddle, E. L., Fleckenstein, A. E., and Hanson, G. R. (2005). Role of monoamine transporters in mediating psychostimulant effects. AAPS J. 7, E847-E851. doi: 10.1208/aapsj070481
153. Robertson, B., Kardamakis, A., Capantini, L., Pérez-Fernández, J., Suryanarayana, S. M., Wallén, P., et al. (2014). The lamprey blueprint of the mammalian nervous system. Prog. Brain Res. 212, 337-349. doi: 10.1016/B978-0-444-63488-7.00016-1
154. Rolls, E. T. (1999). The Brain and Emotion. Oxford: University Press.
155. Rosenthal, N. E., Genhart, M., Jacobsen, F. M., Skwerer, R. G., and Wehr, T. A. (1987). Disturbances of appetite and weight regulation in seasonal affective disorder. Ann. N.Y. Acad. Sci. 499, 216-230. doi: 10.1111/j.1749-6632.1987.tb36213.x
156. Sackeim, H., Decina, P., Prohovnik, I., and Malitz, S. (1987). Seizure threshold in electroconvulsive therapy. Effects of sex, age, electrode placement, and number of treatments. Arch. Gen. Psychiatry 44, 355-360. doi: 10.1001/archpsyc.1987.01800160067009
157. Sanacora, G., Mason, G. F., Rothman, D. L., Hyder, F., Ciarcia, J. J., Ostroff, R. B., et al. (2003). Increased cortical GABA concentrations in depressed patients receiving ECT. Am. J. Psychiatry 160, 577-579. doi: 10.1176/appi.ajp.160.3.577
158. Savitz, J., Lucki, I., and Drevets, WC. (2009). 5-HT(1A) receptor function in major depressive disorder. Prog. Neurobiol. 88, 17-31. doi: 10.1016/j.pneurobio.2009.01.009
159. Schildkraut, J. J. (1965). The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 122, 509-522. doi: 10.1176/ajp.122.5.509
160. Seminowicz, D. A., Mayberg, H. S., McIntosh, A. R., Goldapple, K., Kennedy, S., Segal, Z., et al. (2004). Limbic-frontal circuitry in major depression: a path modeling metanalysis. Neuroimage 22, 409-418. doi: 10.1016/j.neuroimage.2004.01.015
161. Sen, S., Duman, R., and Sanacora, G. (2008). Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analysis and implications. Biol. Psychiatry 64, 527-532. doi: 10.1016/j.biopsych.2008. 05.005
162. Sewards, T. V., and Sewards, M. A. (2003). Representations of motivational drives in mesial cortex, medial thalamus, hypothalamus and midbrain. Brain Res. Bull. 61, 25-49. doi: 10.1016/S0361-9230(03)00069-8
163. Sibug, R. M., Compaan, J. C., Meijer, O. C., Van der Gugten, J., Olivier, B., and De Kloet, E. R. (1998). Flesinoxan treatment reduces 5-HT1A receptor mRNA in the dentate gyrus independently of high plasma corticosterone levels. Eur. J. Pharmacol. 353, 207-214. doi: 10.1016/S0014-2999(98)00417-8
164. Sinclair, L. I., Christmas, D. M., Hood, S. D., Potokar, J. P., Robertson, A., Isaac, A., et al. (2009). Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br. J. Psychiatry 194, 483-490. doi: 10.1192/bjp.bp.107.048371
165. Skene, D. J., and Arendt, J. (2007). Circadian rhythm sleep disorders in the blind and their treatment with melatonin. Sleep Med. 8, 651-655. doi: 10.1016/j.sleep.2006.11.013
166. Sodhi, M. S., and Sanders-Bush, E. (2004). Serotonin and brain development. Int. Rev. Neurobiol. 59, 111-174. doi: 10.1016/S0074-7742(04)59006-2
167. Srinivasan, V., Pandi-Perumal, S. R., Trakht, I., Spence, D. W., Hardeland, R., Poeggeler, B., et al. (2009). Pathophysiology of depression: role of sleep and the melatonergic system. Psychiatry Res. 165, 201-214. doi: 10.1016/j.psychres.2007.11.020
168. Stahl, S. M. (1998). Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. J. Clin. Psychiatry 59(Suppl. 4), 5-14.
169. Stahl, S. M. (2008). Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 3rd Edn. NewYork, NY: Cambridge University Press.
170. Stahl, S. M. (2009). Mechanismof actionof trazodone: a multifunctional drug. CNS Spectr. 14, 536-546. doi: 10.1017/S1092852900024020
171. Stahl, S. M., and Felker, A. (2008). Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 13, 855-870. doi: 10.1017/S1092852900016965
172. Stokes, P. E. (1995). The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. Eur. Neuropsychopharmacol. 5, 77-82. doi: 10.1016/0924-977X(95)00039-R
173. Studd, J., and Nappi, R. E. (2012). Reproductive depression. Gynecol. Endocrinol. 28, 42-45. doi: 10.3109/09513590.2012.651932
174. Stuss, D. T., and Knight, R. T. (eds.). (2002). Principles of Frontal Lobe Function. Oxford: Oxford University Press.
175. Subhash, M. N., Srinivas, B. N., Vinod, K. Y., and Jagadeesh, S. (2000). Modulation of 5-HT1A receptor mediated response by fluoxetine in rat brain. J. Neural Transm. 107, 377-387. doi: 10.1007/s007020050032
176. Sugrue, M. F. (1983). Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning. Pharmacol. Ther. 21, 1-33. doi: 10.1016/0163-7258(83)90065-7
177. Suri, D., and Vaidya, V. A. (2013). Glucocorticoid regulation of brain-derived neurotrophic factor: relevance to hippocampal structural and functional plasticity. Neuroscience 239, 196-213. doi: 10.1016/j.neuroscience.2012.08.065
178. Taher, T. R., Salzberg, M., Morris, M. J., Rees, S., and O’Brien, T. J. (2005). Chronic low-dose corticosterone supplementation enhances acquired epileptogenesis in the rat amygdala kindling model of TLE. Neuropsychopharmacology 30, 1610-1616. doi: 10.1038/sj.npp.1300709
179. Tanti, A., and Belzung, C. (2013). Neurogenesis along the septo-temporal axis of the hippocampus: are depression and the action of antidepressants region-specific? Neuroscience 252, 234-252. doi: 10.1016/j.neuroscience.2013.08.017
180. Terman, M., and Terman, J. S. (2005). Light therapy for seasonal and nonseasonal depression: efficacy, protocol, safety, and side effects. CNS Spectr. 10, 647-663. doi: 10.1017/S1092852900019611
181. Thase, M. E. (1998). Depression, sleep, and antidepressants. J. Clin. Psychiatry 59, 55-65.
182. Tichomirowa, M. A., Keck, M. E., Schneider, H. J., Paez-Pereda, M., Renner, U., Holsboer, F., et al. (2005). Endocrine disturbances in depression. J. Endocrinol. Invest. 28, 89-99. doi: 10.1007/BF03345535
183. Tölle, R. (1991). Diurnal variations of symptoms of depression. Fortschr. Neurol. Psychiatr. 59, 103-116. doi: 10.1055/s-2007-1000684
184. Tsatsanis, C., Dermitzaki, E., Venihaki, M., Chatzaki, E., Minas, V., Gravanis, A., et al. (2007). The corticotropin-releasing factor (CRF) family of peptides as local modulators of adrenal function. Cell. Mol. Life Sci. 64, 1638-1655. doi: 10.1007/s00018-007-6555-7
185. Tsuno, N., Besset, A., and Ritchie, K. (2005). Sleep and depression. J. Clin. Psychiatry 66, 1254-1269. doi: 10.4088/JCP.v66n1008
186. Valentino, R. J., and Foote, S. L. (1988). Corticotropin-releasing hormone increases tonic but not sensory-evoked activity of noradrenergic locus coeruleus neurons in unanesthetized rats. J. Neurosci. 8, 1016-1025.
187. Van Praag, H. M. (1982). Depression. Lancet 2, 1259-1264. doi: 10.1016/S0140-6736(82)90115-5
188. Van Praag, H. M., and Korf, J. (1971). Endogenous depressions with and without disturbances in the 5-hydroxytryptamine metabolism: a biochemical classification? Psychopharmacologia 19, 148-152. doi: 10.1007/BF00402638
189. Velasquez, K. M., Molfese, D. L., and Salas, R. (2014). The role of the habenula in drug addiction. Front. Hum. Neurosci. 8:174. doi: 10.3389/fnhum.2014.00174
190. Viswanath, H., Carter, A. Q., Baldwin, P. R., Molfese, D. L., and Salas, R. (2014). The medial habenula: still neglected. Front. Hum. Neurosci. 7:931. doi: 10.3389/fnhum.2013.00931
191. Wang, H.-T., Han, F., and Shi, Y.-X. (2009). Activity of the 5-HT1A receptor is involved in the alteration of glucocorticoid receptor in hippocampus and corticotropin-releasing factor in hypothalamus in SPS rats. Int. J. Mol. Med. 24, 227-231. doi: 10.3892/ijmm_00000225
192. Warburton, E. C., and Brown, M. W. (2010). Findings from animals concerning when interactions between perirhinal cortex, hippocampus and medial prefrontal cortex are necessary for recognition memory. Neuropsychologia 48, 2262-2272. doi: 10.1016/j.neuropsychologia.2009.12.022
193. Wiles, N., Thomas, L., Abel, A., Ridgway, N., Turner, N., Campbell, J., et al. (2013). Cognitive behavioral therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet 381, 375-384. doi: 10.1016/S0140-6736(12)61552-9
194. Wirz-Justice, A. (2006). Biological rhythm disturbances in mood disorders. Int. Clin. Psychopharmacol. 21, S11-S15. doi: 10.1097/01.yic.0000195660.37267.cf
195. Wirz-Justice, A. (2009). Fromthe basic neuroscience of circadian clock function to light therapy for depression: on the emergence of chronotherapeutics. J. Affect. Disord. 116, 159-160. doi: 10.1016/j.jad.2009.04.024
196. Zald, D. H., and Rauch, S. L. (eds.). (2006). The Orbitofrontal Cortex. Oxford: Oxford University Press.
197. Zhao, H., Zhang, B. L., Yang, S. J., and Rusak, B. (2015). The role of lateral habenula-dorsal raphe nucleus circuits in higher brain functions and psychiatric illness. Behav. Brain Res. 277, 89-98. doi: 10.1016/j.bbr.2014.09.016
198. Zhou, J., Cao, X., Mar, A. C., Ding, Y. Q., Wang, X., Li, Q., et al. (2014). Activation of postsynaptic 5-HT1A receptors improve stress adaptation. Psychopharmacology (Berl). 231, 2067-2075. doi: 10.1007/s00213-013-3350-z